Redwood Pharma initiates toxicological safety studies
Redwood Pharma AB (publ) now begins toxicological safety studies for its drug development project RP101. The results will initially be incorporated into the Company’s application for permission to perform the clinical Phase II trial, which represents the next stage of development for RP101. Development work continues according to plan.The Company’s drug development project RP101, a treatment for chronic dry eye disease, will undergo two important phases during 2017. The first, which begins immediately, is regulatory toxicology testing in animal models that will demonstrate that the RP101